
Aura Biosciences, Inc.
AURANASDAQHealthcare● Active
$6.48
$-0.16(-2.34%)
Market Cap$415693550
P/E Ratio—
52W High$9.535
52W Low$4.73
Aura Biosciences, Inc.(AURA)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · AURA · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.09B | $0.07B | $0.06B | $0.04B | $0.03B |
| G&A Expenses | $0.02B | $0.02B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.11B | $0.10B | $0.08B | $0.06B | $0.04B |
| Operating Income | ($0.11B) | ($0.10B) | ($0.08B) | ($0.06B) | ($0.04B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.09B) | ($0.08B) | ($0.06B) | ($0.04B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.11B) | ($0.09B) | ($0.08B) | ($0.06B) | ($0.04B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-1.58 |
| Wtd Avg Shares | 0.06B | 0.05B | 0.04B | 0.03B | 0.03B |
| EBITDA | ($0.11B) | ($0.09B) | ($0.08B) | ($0.06B) | ($0.03B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · B
深入了解Aura Biosciences, Inc.
关于Aura Biosciences, Inc.(AURA)损益表
Aura Biosciences, Inc.(AURA)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,AURA实现营收$0.00B,毛利润$0.00B(毛利率—),净利润($0.11B)(净利率—)。
常见问题
AURA · 4 问Aura Biosciences, Inc.(AURA)2025财年营收为$0.00B,同比down—%。
AURA revenueAURA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08